Recent MTNB News
- Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 03/15/2023 08:05:00 PM
- Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023 • GlobeNewswire Inc. • 03/08/2023 12:00:00 PM
- Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID • GlobeNewswire Inc. • 03/02/2023 12:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/30/2023 09:01:51 PM
- Matinas BioPharma Provides Business Update and 2023 Strategic Outlook • GlobeNewswire Inc. • 01/30/2023 09:01:00 PM
- Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023 • GlobeNewswire Inc. • 01/23/2023 12:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/12/2023 12:00:42 PM
- Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids • GlobeNewswire Inc. • 01/12/2023 12:00:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/22/2022 04:25:46 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/22/2022 04:24:31 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/22/2022 04:22:56 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/22/2022 04:20:32 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/22/2022 04:19:02 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/14/2022 10:44:02 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/02/2022 08:03:18 PM
- Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress • GlobeNewswire Inc. • 11/02/2022 08:02:00 PM
- Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2022 Operational and Financial Results on November 2, 2022 • GlobeNewswire Inc. • 10/27/2022 11:00:00 AM
- Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90% • GlobeNewswire Inc. • 10/21/2022 11:48:01 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 10/21/2022 11:02:06 AM
- Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference • GlobeNewswire Inc. • 10/21/2022 11:00:00 AM
- Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022 • GlobeNewswire Inc. • 10/19/2022 11:10:00 AM
- Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022 • GlobeNewswire Inc. • 10/12/2022 11:00:00 AM
- Proxy Statement (definitive) (def 14a) • Edgar (US Regulatory) • 09/22/2022 09:02:26 PM
- Matinas BioPharma Announces Chairman Succession Plan • GlobeNewswire Inc. • 09/21/2022 11:00:00 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 09/13/2022 11:01:55 AM
FEATURED Fineqia's EEA Unit Receives Approval of Base Prospectus for Issuing Exchange Traded Notes (ETNs) • Mar 28, 2023 9:37 AM
FEATURED Usha Resources Enters Hard-Rock Lithium Space with Acquisition of Significant Ontario Land Package with Highly Evolved LCT-Pegmatites • Mar 28, 2023 8:26 AM
FEATURED Edison Lithium Provides Update on Spin-Out of Cobalt Assets • Mar 28, 2023 8:09 AM
FEATURED Epazz Holdings: ZenaDrone, Inc. 1000 AI Predictive Received a Letter of Support from the US Airforce for Drone Cargo Delivery and Intent to Use ZenaDrone 1000 Platform • Mar 28, 2023 7:11 AM
Metatron Releases All-in-One Artificial Intelligence Mobile Apps for iPhone and Android • MRNJ • Mar 27, 2023 9:00 AM
Memorandum of Understanding With Miranda Water Treatment Systems and Rainmaker Worldwide Inc. Extended • RAKR • Mar 27, 2023 8:50 AM